BPC-157 and TB-500 get paired because they are thought to act on repair from two different directions: BPC-157 is associated with blood-vessel formation and fibroblast activity at the site, while thymosin beta-4 binds actin, the protein that lets cells move. Different mechanisms, no shared receptor, so the logic of combining them is reasonable on paper.
What the pairing does not have is a single human trial testing the two together. Not one. Everything written about the “Wolverine stack” extrapolates from separate animal studies plus a small amount of human data on full-length thymosin beta-4. This guide covers what each compound actually is, where the evidence is strong and where it runs out, the blend-versus-separate-vials question, real Canadian costs, and the two things that genuinely matter before buying either.
Why these two get paired
The nickname came from forums, not from a laboratory. The idea is simple enough: if one compound is associated with building new blood supply and matrix at an injury site, and the other is associated with cell migration into that site, then running both should cover more of the repair process than either alone.
Three things keep the pairing popular:
- They do not compete. There is no shared receptor and no known overlapping pathway, so there is no obvious reason they would cancel each other out.
- They are the two most-studied repair peptides. Between them they account for most of the published tissue-repair literature in this category.
- Vendors sell them as a blend. Once a combined vial exists, the combination becomes the default rather than a choice.
“Reasonable on paper” is not evidence. No published study has tested BPC-157 and TB-500 together in humans or, as far as we can find, head-to-head against either alone in a controlled animal model. Any site telling you the stack outperforms single compounds is making that up. What follows is what is actually known about each half.
BPC-157 in plain terms
BPC-157 is a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein found in human gastric juice. Researchers call it a stable gastric pentadecapeptide because, unusually for a peptide, it resists breakdown in acidic conditions.
| Length | 15 amino acids |
| Molecular weight | ~1,419 Da |
| Half-life | Under 30 minutes in rats and dogs |
| Research focus | Gastrointestinal lesions, tendon and muscle models, blood-vessel formation |
| Human trials | No published randomized controlled trial; fewer than 20 people with documented outcomes |
The literature is large but narrow: over thirty years of work, dominated by one research group in Zagreb, almost entirely in animals. A 2025 systematic review in HSS Journal screened 544 articles, included 36, and classified every single one as level IV or V evidence — the lowest tiers. Depth of publication is not the same as strength of evidence.
TB-500 in plain terms, and the fragment problem
This is where most guides go wrong, so it is worth slowing down.
Thymosin beta-4 (Tβ4) is a 43-amino-acid protein found in nearly every human cell. Its main job is binding actin, the building block cells use to change shape and move. It has been through real clinical trials: a phase 1 intravenous study in healthy volunteers reported no dose-limiting toxicity at doses up to 1,260 mg, a first-in-human phase 1 of recombinant Tβ4 in China reported it was well tolerated, and eye-drop formulations reached phase 2 and 3.
“TB-500” is a trade name, not a scientific one. Depending on the supplier it means either a synthetic copy of the full 43-amino-acid protein, or a 7-amino-acid fragment (Ac-LKKTETQ, the 17–23 region believed to drive actin binding).
| Full-length Tβ4 | 7-amino-acid fragment | |
|---|---|---|
| Molecular weight | ~4,960 Da | ~890 Da |
| Human trial data | Phase 1 through phase 3 | None published |
| What the safety record covers | This molecule | Essentially nothing in humans |
The molecular weight on the certificate of analysis tells you which molecule you have. Roughly 4,960 Da means full-length thymosin beta-4. Roughly 890 Da means the short fragment. When someone says “TB-500 has human trial data,” they are citing Tβ4 trials — which do not automatically apply to a fragment. See how to read a COA.
How they are said to fit together
The theoretical division of labour looks like this:
| BPC-157 | TB-500 / Tβ4 | |
|---|---|---|
| Associated mechanism | Angiogenesis (new blood vessels), fibroblast migration, growth-factor receptor expression | Actin binding, enabling cell migration |
| Rough analogy | Building the supply road and the materials depot | Getting the crew to the site |
| Research weighting | Gut, tendon, muscle | Cornea, heart, skin wounds |
| Speed profile | Cleared in under 30 minutes | Longer for the full protein; fragment uncharacterised in humans |
| Shared pathway? | None identified. This is the basis of the “they complement each other” argument. | |
We unpack the mechanics further in BPC-157 vs TB-500.
What the evidence actually supports
Here is the honest grading, claim by claim.
| Claim | Evidence level |
|---|---|
| BPC-157 affects tissue repair in animal models | Reasonable. Large animal literature, though concentrated in one group and low-tier by design. |
| Full-length Tβ4 is tolerated in humans short-term | Reasonable. Phase 1 through 3 data exist. |
| BPC-157 works in humans | Unproven. No controlled trial. FDA staff described “a general lack of quality data” in July 2026. |
| The 7-amino-acid TB-500 fragment works in humans | Unproven. No published human trials at all. |
| The two together outperform either alone | No evidence. No combined study exists in humans or, that we can find, in controlled animal comparisons. |
| The stack is safe long-term | Unknown. No long-term human safety data for either compound. |
Blend or two separate vials?
This is the practical question people actually have, and it has a clear answer in each direction depending on what you are doing.
| Combined blend vial | Two separate vials | |
|---|---|---|
| Reconstitution steps | One vial, one diluent volume, one calculation | Two of everything |
| Ratio control | Fixed by the manufacturer | Fully independent |
| Isolating a variable | Impossible — you cannot tell which component did what | Possible: run one, then the other |
| If one component causes a problem | You have to stop both | Stop one, keep the other |
| COA clarity | Should report each component separately — check that it does | One COA per compound, simpler to verify |
| Cost | Usually lower per total mg | Usually higher, but you control quantities |
Blends are a convenience and a cost decision, not a scientific one. If the goal is to observe anything attributable, separate vials are the only format that lets you tell the two apart. If the goal is simplicity and a lower price per milligram, the blend is the practical choice. There is no evidence that pre-mixing improves anything.
What it costs in Canada
Current TrueLabs pricing, so you can do the arithmetic rather than guess:
| Product | Sizes | From |
|---|---|---|
| BPC-157 | 2 mg · 5 mg · 10 mg | $22 |
| TB-500 | 2 mg · 5 mg · 10 mg | $55 |
| BPC-157 + TB-500 blend | 10 mg · 20 mg · 30 mg total | $70 |
| Bacteriostatic water | 3 mL · 10 mL | $7 |
Two cost notes that are easy to miss:
- Bacteriostatic water is not optional. Lyophilized powder has to be reconstituted, and sterile water without preservative is single-use. Budget for it in the first order rather than discovering it later. See bacteriostatic vs sterile water.
- Domestic shipping removes hidden costs. Orders that cross a border can attract CBSA holds and brokerage fees, and Health Canada says it works with the CBSA to stop unauthorized peptide shipments. We cover the real arithmetic in Canadian vs imported peptides.
If your interest is skin and recovery rather than a specific injury, the broader blends are worth comparing: GLOW70 adds GHK-Cu to the same two compounds, and KLOW80 adds KPV on top of that. Our breakdown is in Wolverine vs GLOW vs KLOW.
See the BPC-157 + TB-500 blend and its COA →
Reconstitution, storage and the maths
Reconstitution is a dilution problem, and the arithmetic is the same for one compound or a blend: concentration equals milligrams divided by millilitres. A 10 mg vial in 2 mL gives 5 mg/mL, which is 5,000 mcg/mL.
Our peptide reconstitution calculator does the conversion, and how to reconstitute peptides covers the lab method step by step. Two points specific to this pairing:
- A blend has one concentration for the vial, but each component has its own. If a 20 mg blend is split evenly, a 20 mg vial in 2 mL is 10 mg/mL total — but only 5 mg/mL of each component. Blend COAs should state the split; if yours does not, that is a question for the supplier.
- Storage clocks are identical for both. Lyophilized powder in the freezer keeps long term; reconstituted solution in bacteriostatic water is commonly worked to about 28 days refrigerated. Details in how long reconstituted BPC-157 lasts.
What a realistic timeline looks like
Neither compound can outrun the biology of connective tissue, and that biology is well described independently of peptides.
| Phase | Window | What is happening |
|---|---|---|
| Inflammatory | First ~24 hours, settling over days | Debris cleared, fibroblasts recruited |
| Proliferative | Days to several weeks | New, disorganised collagen laid down |
| Remodelling | Begins ~week 6, scar-like by ~week 10, continues for months | Cross-linking, reorganisation along lines of load, strength returns |
Which means: gut tissue turns over in days, muscle in weeks, tendon and ligament over months. Evaluating a tendon at week four is reading the result before the relevant phase has started. The full breakdown, including why most individual “it worked” stories cannot be attributed, is in how long BPC-157 takes to work.
Side effects of each half
| BPC-157 | TB-500 | |
|---|---|---|
| Controlled human safety data | None | Full-length Tβ4: reported well tolerated in phase 1–3. Fragment: none. |
| Animal toxicity | A 2020 preclinical evaluation reported no serious toxicity in mice, rats, rabbits or dogs | No major toxicity reported |
| Commonly reported online | Nausea, insomnia, anxiety — all anecdotal, none measured | Fatigue, headache, injection-site redness — all anecdotal |
| Most concrete risk | Product quality: wrong dose, contaminants, wrong molecule | Same, plus the theoretical cancer question below |
Deeper coverage: BPC-157 side effects and TB-500 side effects.
The cancer question, stated plainly
Anti-doping agencies are blunt about thymosin beta-4. Sport Integrity Australia warns of a “serious concern that it increases the spread and growth of cancer cells.”
The concern is mechanistic rather than case-based. Tβ4 helps cells move and helps new blood vessels form. Those are useful for healing, and they are two things tumours also rely on. Laboratory and tissue studies have found higher Tβ4 levels in some cancers, and in colorectal cancer, higher expression has been associated with invasion and distant metastasis.
There is no evidence that TB-500 causes cancer in a healthy person. There is a credible theoretical reason it could help an existing tumour grow or spread, and no study has been long enough or large enough to rule it out. That is precisely why a physician would hesitate with anyone who has a personal history of cancer. BPC-157 carries a parallel theoretical question through angiogenesis, covered in does BPC-157 cause cancer.
Who this does not suit
- Anyone with a personal or family history of cancer. The mechanistic concern above applies to both halves, and neither has long-term data.
- Athletes in tested sport. BPC-157 is prohibited at all times under WADA category S0; thymosin beta-4 and its fragments under S2. Strict liability applies, and a research label is not a defence.
- Anyone without a clear diagnosis. If the pain is nerve-related, referred, or inflammatory arthritis, a tissue-repair mechanism has nothing to act on.
- Anyone who wants to know what is working. Running two unproven compounds simultaneously guarantees the result is uninterpretable.
Common mistakes
- Assuming TB-500 trial data applies to the fragment. Check the molecular weight on the COA. It is the single most informative number on the document.
- Starting both at once, then trying to attribute the result. Two variables, one observation, no conclusion.
- Judging tendon outcomes before week six. Remodelling has not begun.
- Buying a blend without a component breakdown. “20 mg blend” tells you nothing about the split.
- Forgetting the diluent. Lyophilized powder is not usable until reconstituted.
- Treating complete rest as recovery. Remodelling organises collagen along lines of load; a physiotherapist sets appropriate progression.
- Accepting a generic COA. It must match your lot number.
First order checklist
Legal status in Canada
| Health Canada | Neither is authorized. Both BPC-157 and TB-500 are named in Health Canada’s April 9, 2026 public advisory on unauthorized injectable peptides, and both were among products seized from Canada Peptide in 2025. The advisory states that “research use only” labelling does not make these products legal or exempt from regulatory requirements. |
|---|---|
| FDA (USA) | Neither is approved. In July 2026 an FDA advisory committee narrowly recommended allowing pharmacy compounding of both with a prescription; the vote is non-binding and is not a drug approval. |
| WADA | BPC-157 prohibited under S0; thymosin beta-4 and fragments under S2. Both at all times. |
Glossary
| Angiogenesis | Formation of new blood vessels. Useful for healing; also something tumours depend on. |
| Actin | The structural protein cells use to change shape and move. What thymosin beta-4 binds. |
| Lyophilized | Freeze-dried. The dry powder form peptides ship in. |
| Reconstitution | Dissolving that powder in a diluent, usually bacteriostatic water. |
| COA | Certificate of analysis: the lab report for a specific lot. |
| Level IV / V evidence | Case series and expert opinion, the lowest tiers of the evidence hierarchy. |
| Strict liability | In anti-doping, the athlete is responsible for what is in their body regardless of intent. |
Frequently asked questions
Cliquez sur une question pour afficher la réponse.
Can you take BPC-157 and TB-500 together?
They are commonly combined in research settings and sold as a blend, and no shared pathway or known interaction has been identified. However, no published human study has tested the two together, so there is no evidence that the combination outperforms either alone.
What is the Wolverine stack?
An informal name for combining BPC-157 and TB-500 for tissue-repair research. The name comes from online communities, not from any laboratory or published study.
Is the blend better than buying two separate vials?
Neither is scientifically better. A blend is simpler and usually cheaper per milligram; separate vials let you control the ratio and tell which compound is responsible for what you observe.
Can BPC-157 and TB-500 be mixed in the same syringe?
Compatibility of two reconstituted peptides in a single syringe has not been formally studied, which is why pre-made blends exist. If you want them combined, a blend manufactured and tested as one product is the format with a COA behind it.
How do I know whether my TB-500 is the full protein or the fragment?
Check the molecular weight on the certificate of analysis: roughly 4,960 Da indicates full-length thymosin beta-4, roughly 890 Da indicates the acetylated 7-amino-acid fragment.
How long does the Wolverine stack take to work?
There is no established human answer for either compound. The underlying tissue timeline is fixed: inflammation settles over about a day, collagen is laid down over weeks, and remodelling starts around week six and continues for months.
Does TB-500 cause cancer?
No study shows that it does. Because thymosin beta-4 promotes cell movement and blood-vessel growth, and higher levels have been linked to metastasis in some cancers, researchers treat it as a theoretical risk, particularly for anyone with existing cancer.
What is the difference between the Wolverine blend, GLOW and KLOW?
The Wolverine pairing is BPC-157 plus TB-500. GLOW adds GHK-Cu to those two. KLOW adds KPV on top of GLOW. More components means less ability to attribute any result to a specific compound.
How much does the stack cost in Canada?
At TrueLabs, BPC-157 starts at $22, TB-500 at $55, and the combined blend at $70, plus $7 for bacteriostatic water. Blends are generally cheaper per total milligram than buying components separately.
Do I need bacteriostatic water?
Yes, for any vial used more than once. Lyophilized powder must be reconstituted, and sterile water contains no preservative so it is single-use.
How should I store a blend vial?
Sealed lyophilized powder keeps long term in the freezer and several months refrigerated. Once reconstituted with bacteriostatic water, a common working rule is about 28 days at 2–8 °C.
Are BPC-157 and TB-500 legal in Canada?
Neither is authorized by Health Canada. Both are named in its April 2026 advisory on unauthorized injectable peptides, which also states that research-use-only labelling does not make a product legal.
Are they banned in sport?
Yes. BPC-157 falls under WADA category S0 and thymosin beta-4 under S2, both prohibited at all times, with strict liability.
Why does my blend look slightly off-white?
Lyophilized peptide is normally a white cake or powder. Discolouration, a collapsed or wet-looking cake, or particles after reconstitution are reasons to stop and check the COA and storage history.
Related reading
- How long does BPC-157 take to work?
- BPC-157 vs TB-500: roads vs trucks
- Wolverine vs GLOW vs KLOW
- How to spot fake or underdosed peptides
- Canadian vs imported peptides
References
- Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PubMed
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022;13:1026182. PubMed
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157. Regul Toxicol Pharmacol. 2020;114:104665. DOI
- Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223–229. PubMed
- A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. 2021. PMC
- Wang WS, et al. Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. 2004. PubMed
- Sport Integrity Australia. Thymosin beta-4. Sport Integrity Australia
- ShoulderDoc. Tendon healing mechanobiology. ShoulderDoc
- Health Canada. Think twice before injecting peptides bought online. Public advisory, April 9, 2026. Health Canada
- Health Canada. Advisory RA-77807 (Canada Peptide), August 1, 2025. Recalls and Safety Alerts
All TrueLabs products are sold for in vitro and laboratory research use only. They are not intended for human or veterinary use. Nothing in this article is medical advice or a dosing protocol. If you have an injury, or any history of cancer, please talk to a doctor.